Valuation and Deal Support

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...
Learn More

Clinical strategy, medical oversight and clinical due diligence

Alacrita's consulting team supports a number of pharmaceutical & biotech companies with medical and clinical strategy. We have particular depth in oncology, but also have expertise in infectious...
Learn More

Observer on BoD for private equity investor

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD...
Learn More

Life Science Technology Scouting

Asset scouting for a well-capitalized Swiss pharma company Alacrita been engaged by a well-capitalized Swiss pharma company to scout and identify early stage in-licensing opportunities from the New...
Learn More

Due diligence on a diagnostics investment opportunity

Challenge: A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...
Learn More

Ex-US diagnostics business development strategy

Alacrita's diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded...
Learn More

Cancer immunotherapy consulting

Alacrita Consulting's founders worked together for over 10 years at Onyvax, a London-based cancer immunotherapy company backed by SR One. We have conducted a number of consulting projects in the...
Learn More

Strategy for biomarker identification technology

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of...
Learn More

Novel Antibody Screening Technology

Technology Consulting: Novel Antibody Screening Technology Alacrita's antibody consultants were asked to help assess the market potential and develop a commercialization strategy for a novel antibody...
Learn More

Business Development and Partnering Support

Valuations For a biotech company engaged in licensing discussions with a number of major pharmaceutical companies, Alacrita developed rNPV valuations for each program. This 'theoretical' valuation...
Learn More

Intellectual Property Analysis & Strategy

Due diligence For a financial investor, Alacrita conducted an IP assessment on a late stage cell therapy  investment opportunity. The assessment revealed that the US and EPO patents relied on just...
Learn More

Antibodies

Target Assessment and intellectual property For a mid-cap pharmaceutical company seeking to establish a biologics pipeline through partnership with a mAb development boutique, Alacrita assessed the...
Learn More
Previous
1 ... 8 9 10 11 12
Next
Content not found

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Life Science Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.